Detalhe da pesquisa
1.
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study.
Breast Cancer Res Treat
; 133(1): 237-46, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22286314